elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Papers
Communities
Institutions
beta
Research Intelligence
Lab
API & MCP
Pricing
Log in
Sign up
Home
/
Subjects
/
Viral entry
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Viral entry
RIS
0.001
(Research Intensity Score)
Papers
78
Top papers
Potent antiviral effect of silver nanoparticles on SARS-CoV-2
2020 · 438 citations
Aedes aegypti and dengue: insights into transmission dynamics and viral lifecycle
2025 · 34 citations
Lessons in self-defence: inhibition of virus entry by intrinsic immunity
2021 · 157 citations
SARS-CoV-2 Productively Infects Human Gut Enterocytes
2020 · 269 citations
Macrocycle-based PROTACs selectively degrade cyclophilin A and inhibit HIV-1 and HCV
2025 · 28 citations
Newest papers
Glycyrrhizic Acid-Modified Gold Nanoparticles Show Inhibitory Activity Against PRRSV and SARS-CoV-2 Pseudovirus In Vitro
2026 · 1 citations
Probing Glycan-Gold Nanoparticle Architectures: Glycan Type, Density, and Linker Length, Governing Multivalent Lectin Binding and Viral Inhibition
2026 · 1 citations
ACE2-PNA conjugates exploit viral endocytosis for targeted intracellular delivery and exhibit dual antiviral efficacy against SARS-CoV-2
2026
Nicotine and cotinine enhance SARS-CoV-2 entry through distinct but complementary mechanisms in human respiratory epithelial cells
2026
Non-GMO surface display of VP28 on Pediococcus pentosaceus for oral protection against white spot syndrome virus in shrimp
2026
A sample from the 78 top papers behind Viral entry.
Create a free account to browse them all →
Viral entry's history
Research intensity over time
Explore Viral entry's full history
Hover any year for its value and switch resolutions with a free account. Personal adds monthly detail and the historical-intensity (HRI) line.
Create a free account
Already have an account?
Log in
to explore the data.
Close ✕
Viral entry's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link